北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学公共卫生学院  > 期刊论文
学科主题: 公共卫生
题名:
Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis
作者: Sun, Feng1,2,3; Yu, Kai4; Wu, Shanshan1; Zhang, Yuan1; Yang, Zhirong1; Shi, Luwen2; Ji, Linong5; Zhan, Siyan1
关键词: Glucagon-like peptide-1 receptor agonists ; Cardiovascular safety ; Efficacy ; Network meta-analysis ; Type 2 diabetes mellitus
刊名: DIABETES RESEARCH AND CLINICAL PRACTICE
发表日期: 2012-12-01
DOI: 10.1016/j.diabres.2012.09.004
卷: 98, 期:3, 页:386-395
收录类别: SCI
文章类型: Review
WOS标题词: Science & Technology
类目[WOS]: Endocrinology & Metabolism
研究领域[WOS]: Endocrinology & Metabolism
关键词[WOS]: RANDOMIZED CLINICAL-TRIALS ; MYOCARDIAL-INFARCTION ; ANTIDIABETIC AGENTS ; EXENATIDE TWICE ; PARALLEL-GROUP ; LIRAGLUTIDE ; THERAPIES ; INSULIN ; EFFICACY ; DISEASE
英文摘要:

Aims: Integrating evidence from all randomized controlled trials (RCTs) of glucagon-like peptide-1 receptor agonists (GLP-1s) to assess the safety of cardiovascular disease (CVD) and efficacy of glycemic control.

Methods: Besides performing pairwise meta-analysis, network meta-analysis of all RCTs was used to combine direct and indirect estimates of the effect of GLP-1 with placebo, active comparator drugs (ACD), or another GLP-1 agent with treatment duration >8 weeks in T2DM patients, 15,883 for CVD safety from 45 RCTs and 14,136 for glycemic control from 36 RCTs.

Results: For CVD safety, both of the results from pairwise and network meta-analysis failed to demonstrate significant difference between any two comparators. For glycemic control, the effect of any GLP-1 was better than placebo, but no difference was found between GLP-1s. We also found that liraglutide was the only GLP-1 drug shown to be more effective on improving glycemic control than ACD and exenatide. The results based on direct or indirect estimates were similar for two outcomes.

Conclusion: Our network meta-analysis provides a complete picture of the associations between GLP-1s, ACD and placebo on CVD safety and glycemic control. The GLP-1s are promising candidates for the treatment of T2DM, but more long-term trials are needed to confirm potential CVD safety. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

语种: 英语
所属项目编号: 2010JC15 ; RCZX200923
项目资助者: Doctoral Fund of corps ; High level talent project of Shihezi University ; Tianjin Municipal Health Bureau of industry of key reasearch projects
WOS记录号: WOS:000312133700009
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53501
Appears in Collections:北京大学公共卫生学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Tianjin Fifth Cent Hosp, Dept Orthoped, Tianjin 300450, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China
3.Peking Univ, Int Res Ctr Med Adm, Beijing 100191, Peoples R China
4.Shihezi Univ, Coll Med, Dept Prevent Med, Shihezi 832002, Peoples R China
5.Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100044, Peoples R China

Recommended Citation:
Sun, Feng,Yu, Kai,Wu, Shanshan,et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis[J]. DIABETES RESEARCH AND CLINICAL PRACTICE,2012,98(3):386-395.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Sun, Feng]'s Articles
[Yu, Kai]'s Articles
[Wu, Shanshan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Sun, Feng]‘s Articles
[Yu, Kai]‘s Articles
[Wu, Shanshan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace